Effect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model

Lee, Seung Tae; Maeng, Hoyoung; Chwae, Yong‐Joon; Oh, Deok-Kun; Kim, Yong‐Man; Yang, Woo Ick

doi:10.1007/s12185-008-0041-3

Cited by 14 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tested by mixed lymphocyte reaction [MLR]) and in vivo [108][109][110]. Due to its immaturity, cord blood derived unrestricted somatic stem cells (USSC) express HLA class I (HHCI) at low levels and are negative for MHC class II (MHCII) and are therefore particularly attractive to manipulate or modify graft-versus-host disease (GVHD) [109].…”

Section: Mesenchymal Cord Blood Cells Have Low Immunogenic Propertiesmentioning

confidence: 99%

Cord Blood—An Alternative Source for Bone Regeneration

Jäger

Zilkens

Bittersohl

et al. 2009

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Bone regeneration is one of the best investigated pathways in mesenchymal stromal cell (MSC) biology. Therefore strong efforts have been made to introduce tissue engineering and cell therapeutics as an alternative treatment option for patients with bone defects. This review of the literature gives an overview of MSC biology aiming for clinical application including advantages but also specific challenges and problems which are associated with cord blood derived stromal cell (CB-MSC) as a source for bone regeneration. The use of postnatal CB-MSC is ethically uncomplicated and requires no invasive harvesting procedure. Moreover, most data document a high osteogenic potential of CB-MCS and also low immunoreactivity compared with other MSC types. The expression profile of CB-MSC during osteogenic differentiation shows similarities to that of other MSC types. Within the umbilical cord different MSC types have been characterized which are potent to differentiate into osteoblasts. In contrast to a large number of in vitro investigations there are only few in vivo studies available so far.

show abstract

Section: Mesenchymal Cord Blood Cells Have Low Immunogenic Propertiesmentioning

confidence: 99%

Cord Blood—An Alternative Source for Bone Regeneration

Jäger

Zilkens

Bittersohl

et al. 2009

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

“…130 Moreover, the co-transplantation of hMSCs with CB cells has been shown to increase human hematopoietic engraftment in xenograft recipients, [130][131][132] and even shift the resulting lineage distribution from a B-lymphoid to a myeloid predominance. 133 Though hMSCs have not been shown to enhance the engraftment of primary AML samples, 134 this approach may nonetheless prove to be useful as a means to promote myeloid leukemogenesis in retroviral transduction-transplantation studies.…”

Section: Future Directionsmentioning

confidence: 99%

Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia

Kennedy

Barabé

2008

Leukemia

View full text Add to dashboard Cite

The hematopoietic system produces appropriate levels of blood cells over an individual's lifetime through a careful balance of differentiation, proliferation and self-renewal. The acquisition of genetic and epigenetic alterations leads to deregulation of these processes and the development of acute leukemias. A prerequisite to targeted therapies directed against these malignancies is a thorough understanding of the processes that subvert the normal developmental program of the hematopoietic system. This involves identifying the molecular lesions responsible for malignant transformation, their mechanisms of action and the cell type(s) in which they occur. Over the last 3 decades, significant progress has been made through the identification of recurrent genetic alterations and translocations in leukemic blast populations, and their subsequent functional characterization in cell lines and/or mouse models. Recently, primary human hematopoietic cells have emerged as a complementary means to characterize leukemic oncogenes. This approach enables the process of leukemogenesis to be precisely modeled in the appropriate cellular context: from primary human hematopoietic cells to leukemic stem cells capable of initiating disease in vivo.Here we review the model systems used to study leukemogenesis, and focus particularly on recent advances provided by in vitro and in vivo studies with primary human hematopoietic cells.

show abstract

“…USSC are multipotent and can differentiate into cells of all three germ layer lineages: endodermal (liver, lung) [18,19], ectodermal (nerve) and mesodermal (heart, cartilage, bone, fat and blood) [20,21]. They show a high osteoregenerative potential in vitro [22,23,24] and a low immunogenic profile compared to other adult stem cell types [25]. Due to their immaturity, USSC express HLA class I at low levels and are negative for MHC class II, and they are therefore particularly attractive to manipulate or modify graft-versus-host disease (GVHD) [26].…”

Section: Introductionmentioning

confidence: 99%

Biomechanical Stability and Osteogenesis in a Tibial Bone Defect Treated by Autologous Ovine Cord Blood Cells—A Pilot Study

Herten

Zilkens

Thorey³

et al. 2019

Molecules

View full text Add to dashboard Cite

The aim of this study was to elucidate the impact of autologous umbilical cord blood cells (USSC) on bone regeneration and biomechanical stability in an ovine tibial bone defect. Ovine USSC were harvested and characterized. After 12 months, full-size 2.0 cm mid-diaphyseal bone defects were created and stabilized by an external fixateur containing a rigidity measuring device. Defects were filled with (i) autologous USSC on hydroxyapatite (HA) scaffold (test group), (ii) HA scaffold without cells (HA group), or (iii) left empty (control group). Biomechanical measures, standardized X-rays, and systemic response controls were performed regularly. After six months, bone regeneration was evaluated histomorphometrically and labeled USSC were tracked. In all groups, the torsion distance decreased over time, and radiographies showed comparable bone regeneration. The area of newly formed bone was 82.5 ± 5.5% in the control compared to 59.2 ± 13.0% in the test and 48.6 ± 2.9% in the HA group. Labeled cells could be detected in lymph nodes, liver and pancreas without any signs of tumor formation. Although biomechanical stability was reached earliest in the test group with autologous USSC on HA scaffold, the density of newly formed bone was superior in the control group without any bovine HA.

show abstract

Effect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model

Cited by 14 publications

References 29 publications

Cord Blood—An Alternative Source for Bone Regeneration

Cord Blood—An Alternative Source for Bone Regeneration

Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia

Biomechanical Stability and Osteogenesis in a Tibial Bone Defect Treated by Autologous Ovine Cord Blood Cells—A Pilot Study

Contact Info

Product

Resources

About